论文部分内容阅读
目的探讨培菲康联合舒丽启能治疗肠易激综合征的临床疗效和安全性。方法将2007年1月至2009年12月间开封市鼓楼结核病医院诊断为肠易激综合征的100例患者随机分成A、B两组,每组50例,A组给予培菲康420 mg,每天3次,联合舒丽启能200 mg每天3次进行治疗,疗程4周;B组仅给予舒丽启能200 mg每天3次进行治疗,疗程4周,观察两种方法治疗肠易激综合征的临床疗效。结果 A组50例患者中显效25例,有效19例,无效6例,总有效率为88.0%;B组50例患者中显效15例,有效19例,无效16例,总有效率为68.0%。两组患者疗效比较差异有统计学意义(P<0.01)。结论培菲康联合舒丽启能治疗肠易激综合征疗效肯定。
Objective To investigate the clinical efficacy and safety of combination of Peifei Kang and Shu-Li-Kai in the treatment of irritable bowel syndrome. Methods 100 patients diagnosed as irritable bowel syndrome in Drum Tower Drum Tower Hospital of Kaifeng City from January 2007 to December 2009 were randomly divided into two groups A and B, 50 cases in each group. Group A received Peifei Kang 420 mg, 3 times a day, combined Shuli Kai 200 mg three times a day for treatment, treatment for 4 weeks; B group only given Shureng 200 mg three times a day for treatment, the course of 4 weeks to observe the clinical efficacy of two methods of treatment of irritable bowel syndrome . Results Among 50 patients in group A, 25 cases were markedly effective, 19 cases were effective, 6 cases were ineffective and the total effective rate was 88.0%. In group B, 50 cases were markedly effective in 15 cases, effective in 19 cases and ineffective in 16 cases, with a total effective rate of 68.0% . The difference between the two groups was statistically significant (P <0.01). Conclusions Pefloxacin combined with Shu Li Kai can treat irritable bowel syndrome efficacy.